Tumor progression-dependent angiogenesis in gastric cancer and its potential application

Hsi-Lung Hsieh, Ming-Ming Tsai

Abstract

Despite improvements in the early diagnosis, prognosis and therapeutic strategies for gastric cancer (GC), human GC remains one of the most frequently diagnosed malignant tumors in the world, and the survival rate of GC patients remains very poor. Thus, a suitable therapeutic strategy for GC is important for prolonging survival. Both tumor cells themselves and the tumor microenvironment play an important role in tumorigenesis, including angiogenesis, inflammation, immunosuppression and metastasis. Importantly, these cells contribute to gastric carcinogenesis by altering the angiogenic phenotype switch. The development, relapse and spreading of tumors depend on new vessels that provide the nutrition, growth factors and oxygen required for continuous tumor growth. Therefore, a state of tumor dormancy could be induced by blocking tumor-associated angiogenesis. Recently, several antiangiogenic agents have been identified, and their potential for the clinical management of GC has been tested. Here, we provide an up-to-date summary of angiogenesis and the angiogenic factors associated with tumor progression in GC. We also review antiangiogenic agents with a focus on the anti-vascular endothelial growth factor receptor (VEGFR)-mediated pathway for endothelial cell growth and their angiogenesis ability in GC. However, most antiangiogenic agents have reported no benefit to overall survival (OS) compared to chemotherapy alone in local or advanced GC. In phase III clinical trials, only ramucirumab (anti-VEGFR blocker) and apatinib (VEGFR-TKI blocker) have
reported an improved median overall response rate and prolonged OS and progression-free survival outcomes as a 2nd-line agent combined with chemotherapy treatment in advanced GC. By providing insights into the molecular mechanisms of angiogenesis associated with tumor progression in GC, this review will hopefully aid the optimization of antiangiogenesis strategies for GC therapy in combination with chemotherapy and adjuvant treatment.

Key words: Gastric cancer; Angiogenesis; Vascular endothelial cell; Angiogenic phenotype switch; Anti-angiogenesis; Tumor dormancy

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Tumor angiogenesis in gastric cancer (GC) and antiangiogenic therapies for GC, including information from their preclinical and/or application to clinical trials, are discussed. The antiangiogenic strategies for advanced GC include decreasing the expression of proangiogenic ligands and their receptors, increasing the level of angiogenic inhibitors, and directly targeting the inner walls of endothelial cells. Here, the antiangiogenic strategies mainly focus on decreasing the expression of vascular endothelial growth factor-mediated pathway constituents for advanced GC in phase III clinical trials. Thus, this review provides a brief description of various tumor angiogenic factors for the purposes of diagnosis, prognosis and therapeutics and describes the antiangiogenic agents that are currently being investigated in preclinical and phase III clinical trials. Hopefully, according to the molecular mechanism of tumor angiogenesis, we highlight the accuracy of the diagnosis and prognosis and the selection of the most appropriate therapy for GC patients.

Citation: Hsieh HL, Tsai MM. Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World J Gastrointest Oncol 2019; 11(9): 686-704
URL: https://www.wjgnet.com/1948-5204/full/v11/i9/686.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i9.686

INTRODUCTION

Gastric cancer (GC) has a high incidence throughout the world and a high mortality rate associated with malignant tumors[1-3]. GC might not cause any clinical symptoms at the early stage, resulting in the fact that GC is rarely detected at the early stage[2,3]. However, the five-year survival outcome for late-stage GC patients is only approximately 20%-30% after initial diagnosis[4], and gastrectomy is the major common treatment for GC. Thus, to improve the low survival outcome, it is necessary to develop novel therapeutic strategies for GC[5].

In recent decades, studies on the molecular mechanism of tumor development have focused on the genetic or epigenetic changes in tumor cells, such as the emergence of cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT) and the expression of microRNAs (miRNAs)[6]. However, several studies conducted in recent years found that the tumor microenvironment (TME) strongly influences tumor growth and progression and revealed that the tumor-host interactions determine tumor progression[7,8]. The TME contains extracellular matrix and stromal cells, including ECs, tumor-associated fibroblasts and tumor-associated immune/inflammatory cells, which can regulate tumor progression through autocrine/paracrine cytokines or factors. Furthermore, cancer cells can support the angiogenesis of ECs, and ECs can also help cancer cell proliferation by releasing growth factors. Tumor-associated immune/inflammatory cells can control cancer cell proliferation and metastasis under different conditions, and cancer cells might induce immune cell dysfunction as well as proinflammatory cytokine release. Exosomal miRNAs can alter normal fibroblasts into TAFs for tumor survival, and TAFs can promote tumor proliferation and metastasis. Thus, the TME is also involved in multiple processes, including tumor angiogenesis, inflammation, immunosuppression and metastasis, as shown in Figure 1[9-14].

In 1971, Dr. Folkman and Klagsbrun[15] provided a novel theory stating that all phases of rapid tumor growth are dependent on tumor angiogenesis. At present, it is known that tumor angiogenesis plays a key role in tumor progression, and the
The tumor microenvironment regulates tumor growth, relapse and metastasis. Tumor dormancy can be induced in malignant cancer through several mechanisms, such as epigenetic or genetic changes (cancer stem cells, epithelial-mesenchymal transition, and miRNAs) in the tumor, tumor hypoxia, the angiogenic switch, immune evasion and inflammatory switchover. A change in the tumor microenvironment can facilitate tumor growth/relapse/metastasis and thereby permit the tumor to exit from dormancy through interaction with endothelial cells, tumor-associated fibroblasts, tumor-associated immune/inflammatory cells and the extracellular matrix.

MOLECULAR REGULATION OF TUMOR ANGIOGENESIS IN GC

An increasing number of studies has revealed that tumor growth is strongly associated with tumor angiogenesis[12]. Tumor growth, relapse and metastasis should turn on the “angiogenic switch” to induce tumor growth to a size greater than 1-2 mm. Numerous signals (e.g., epigenetic changes, the TME, CSCs, EMT, and miRNAs) can disturb tumor dormancy, resulting in local tumor proliferation/recurrence or metastasis at a secondary site[13]. The “angiogenic switch” is regulated by angiogenic activators and inhibitors[14,15], and the timing of the “angiogenic switch” can occur before, during or after tumor progression. As will be discussed in the following sections (Table 1), recent studies have shown that the available knowledge on the induction and molecular regulation of tumor angiogenesis has grown rapidly, and several growth factors, growth factor receptors, cytokines and signaling pathways have been identified in GC.

TRANSCRIPTION FACTORS

Hypoxia and hypoxia-inducible factor
Preclinical trial: First, the basement membrane in growing tumor cells is injured locally, and tumor cells immediately experience destruction and hypoxia. Tumor hypoxia is a major force that triggers tumor angiogenesis and activates the expression of hypoxia-inducible factor-1 (HIF-1), which then induces the expression of various proangiogenic factors, including vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR), in cancer cells[16-19]. Moreover, HIF-2 isoforms have similar functions as HIF-1, but HIF-2 mainly activates the expression of erythropoietin (EPO) in kidney and liver cells[20]. Overall, HIF-1 is known as a potential target of anticancer therapy in many cancers[21]. In addition, treatment with HIF-1-specific inhibitors has been studied in animal models, and it has been shown that this treatment results in slowed growth of tumors, decreased
| Biological category | Gene name | Regulator of pro-anti angiogenic types | Antiangiogenic drug | Drug direct target | Preclinical trials: cell line (in vitro)/animal (in vivo) | Clinical application | Prognostic factors (proangiogenic biomarker) |
|---------------------|-----------|--------------------------------------|---------------------|-------------------|--------------------------------------------------------|----------------------|-----------------------------------------------|
| Transcription factor | Hypoxia | Activator | NSAI[82] | COX-1, COX-2 inhibitor | • | ND | ND |
| Growth factor | VEGF family[26-38] | Activator | Aflibercept[22] | Anti-VEGF-A | • | ND | ND |
| | HIF[16-19,22-25] | | Bevacizumab[83-89] | Anti-VEGF-A | | ND | ND |
| | | | IFN[90] | Anti-IFNR | | ND | ND |
| | | | Rapamycin[91] | Anti-VEGFR2 | | ND | ND |
| | | | Neovastat[92] | Anti-VEGF | | ND | ND |
| | | | Aflibercept[22] | Anti-VEGF-A | | ND | ND |
| | PDGF[94,97] | Activator | SU5416 | Multiple receptor | | ND | ND |
| | | | SU6668 | Multiple receptor | | ND | ND |
| | | | Orantinib[94] | Anti-VEGFR2 | | ND | ND |
| | | | Pazopanib[100] | Multiple receptor TKI | | ND | ND |
| | | | Sunitinib (Sutent)[103,104] | Multitargeting TKI | | ND | ND |
| | | | Telatinib | Multitargeting TKI | | ND | ND |
| Cytokine | GP130 | Activator | ND | ND | • | ND | ND |
| | IL-6R[98] | | | | | | |
| | Her2/ Neu[59-62] | Activator | Trastuzumab[90,92] | Anti-Her2/Neu | | ND | ND |
| | Ang-1,3,4[54,46-47] | Activator | ND | ND | • | Ang-1,2 | Liver metastasis |
| | Ang-2[58] | Activator | ND | ND | • | Ang-2 | Poor survival |
| | IL-6[60] | Activator | ND | ND | • | ND | ND |
 IL-8[37,38] | Activator | ND | ND | ● | ND | ND
IL-17[38] | Activator | ND | ND | ● | ND | ND
Tryptase[79,80] | Activator | ND | ND | ● | Tryptase overexpression[81] | ND

| ECM | MMP[82] (107,108) | Activator | Marimastat[107,108] | MMP inhibitor | Bay 12-9566 | AG3340 | Neovastat[83] | ● | ND | ND

GC: Gastric cancer; ND: Not determined; ●: Determined; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; TKI: Tyrosine kinase inhibitor.

angiogenesis and minor vessel maturation[23]. Stoeltzing et al[23] obtained similar results using the dominant negative form of HIF-1 in GC. Chronic infection with *Helicobacter pylori* induces DNA damage by generating reactive oxygen species (ROS) in GC cells[24]. Overaccumulation of ROS might stimulate HIF-1 accumulation and aid tumor angiogenesis in GC[25].

**PROANGIOGENIC LIGANDS AND RECEPTORS**

**VEGF family**

**Preclinical trial:** Growing cancer cells encourage the growth of new blood vessels by secreting VEGF and VEGFR into the surrounding TME, and secreted VEGF binds to VEGFR on the outer surface of ECs. ECs are activated by the VEGF signaling pathway, and this activation induces the growth, survival, vascular permeability and migration of ECs to encourage tumor angiogenesis[30]. To date, various cytokines and a major proangiogenic factor of ECs have been found to be members of the VEGF-A family. The VEGF (homodimers) family of growth factors contains VEGF-A, B, C, D and E and placental growth factor (PIGF), and during angiogenesis[27,28], these growth factors bind to and activate the tyrosine kinase receptors (TKRs) VEGFR-1, VEGFR-2, and VEGFR-3, which are specifically expressed on the surface of ECs and have different affinities for the ligands. Consequently, the downstream TKR signaling proteins activate proliferation-mediating signaling pathways, such as the phosphatidylinositol 3 kinase (PI3K)/AKT, protein kinase C (PKC), and mitogen-activated protein kinase (MAPK; p38 and p42/44) pathways[29-31]. In general, VEGF-A binds to VEGFR-1 and VEGFR-2, PIGF and VEGF-B bind to VEGFR-1, and VEGF-C and VEGF-D bind to VEGFR-2 and VEGFR-3[32-34]. Carmeliet et al[35] reported that among the VEGFs, the *vegfa* gene can lead to embryonic lethality due to serious vascular defects after the loss of only a single allele in mice[34-36]. An in vitro tube formation assay using GC cells cocultured with human umbilical vein endothelial cells (HUVECs) demonstrated proangiogenesis function due to the upregulation of VEGF in GC cells[37]. In a rat model, the blockage of VEGF by a specific siRNA led to reduced proliferation and cell cycle arrest[38]. Moreover, the coreceptor of neuropilins in signaling pathways is activated by other growth factors or VEGFs, and neuropilins bind several growth factors and enhance their function; however, the molecular mechanisms affected by neuropilins remain unclear[39,40]. The above data indicate that GC cells possess proangiogenic abilities by secreting angiogenic cytokines to both stimulate ECs and to support their own growth in an autocrine manner. Furthermore, the growth and invasion of GC cells are mainly controlled by the VEGF-mediated pathway.

**Clinical application:** These discoveries from in vitro and animal models were confirmed in GC patients, and their diagnostic or prognostic abilities were tested in GC patients. Through ELISA, significantly higher preoperative plasma or serum VEGF levels were detected in GC patients compared with healthy control subjects. Importantly, a clinicopathological analysis revealed that higher VEGF expression in the plasma or serum of GC patients was significantly associated with advanced stage, distant metastasis and worse survival outcomes[21,41-47].

**PIGF**

**Preclinical trial:** PIGF is another member of the VEGF family and plays a proangiogenic role in the progression of some tumors[29,30,35,49]. Akrami et al[49,50] reported that the knockdown of PIGF in AGS and MKN-45 cells inhibited the
proliferation, self-renewal capacity, MMP activity, transcription activity and migration of these cells.

Clinical application: Higher PIGF and VEGF levels were detected by ELISA in GC tissues compared with paired noncancerous mucosa tissues. A clinicopathological analysis showed that higher expression of only PIGF in GC patients was significantly associated with tumor stage, distant metastasis and worse survival outcomes.[51]

Fibroblast growth factors, epidermal growth factor, hepatocyte growth factor, and insulin-like growth factor

Preclinical trial: The fibroblast growth factor (FGF) family is a large cytokine family, and some of these cytokines, e.g., FGF-1/-2, bind to different fibroblast growth factor receptors, e.g., FGF R 1-4, to activate the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway. Furthermore, these cytokines can regulate tumor angiogenesis, proliferation, migration and antiapoptosis/survival activities both in vitro and in vivo.[31,52-54]. epidermal growth factor (EGF), hepatocyte growth factor (HGF) and insulin-like growth factor (IGF) reportedly stimulate proangiogenic, proliferation and survival activities similarly to those induced by VEGF[55].

Platelet-derived growth factor

Preclinical trial: Pericytes and smooth muscle cells secrete platelet-derived growth factor (PDGF)-BB, which then binds to PDGFR-β and thereby modulates tumor angiogenesis in ECs.[82,78].

GP130, interleukin-6, and interleukin-6R

Preclinical trial: In a mouse model, the blockage of GP130 inhibits tumor development in the epithelium of the glandular stomach via the STAT 1/3-mediated angiogenesis pathway. These results suggest that the TME and cancer cells secrete interleukin-6 (IL-6) via autocrine or paracrine binding to GP130 or IL-6R[59].

Human epidermal growth factor receptor 2/Neu (HER-2/neu) and EGFR

Preclinical trial: In tumor cells, EGF binds to EGFR and HER-2/neu to activate the PI3K/AKT and RAS-MAPK-mediated pathways, which are involved in the overexpression of VEGF-A. The secretion of VEGF-A from cancer cells can be mediated through the activation of various signaling pathways. Furthermore, these factors act as central regulators of tumor growth and tumor angiogenesis in GC[59-62].

Angiopoietin-1, 2, 3, and 4 (Ang-1, -2, -3, and -4)

Preclinical trial: Ang-1, -2, -3, and -4 biologically serve as growth factors for ECs and can strongly regulate competitive interaction with TIE-2 (TKR), which is expressed on the surface of ECs[63-64]. The binding of Ang-1 to TIR-2 activates TIE-2 phosphorylation via the Ang-1/Tie2-cascade pathway and is involved in the proliferation, migration, inflammation and survival of ECs. Ang-2 is then released from activated ECs and serves as a significant antagonist[65,66]. Additionally, TIE-1 (an orphan receptor) can form a complex with TIE-2 to form heterodimers and compete with Ang-1/TIE-2 interactions and thereby promote inflammation in ECs[66-69]. Inhibition of Ang-1 or Ang-2 shows similar inhibition of cell proliferation in GC cell lines[70-73].

Clinical application: Blank et al[9] found that high expression levels of Ang in serum and tissue from GC patients are associated with poor survival. In addition, the Ang/VEGF ratio in GC and esophageal cancer patients serves as an independent proangiogenic biomarker for the clinical response to chemotherapy[9]. Another group of researchers found that Ang-2 can serve as an independent predictor of OS and liver metastasis in GC patients[80]. Moreover, Aktaş et al[77] found that VEGF, PIGF, and Ang-1 are strongly correlated with OS; thus, these angiogenesis prognostic indices (APIs) could predict survival outcomes in GC patients.

IL-8

Preclinical trial: Tumor-infiltrating macrophages secrete IL-8 and upregulate VEGF to activate EC angiogenesis in GC, as demonstrated in an in vitro assay[71].

IL-17

Preclinical trial: IL-17 stimulates the STAT3-mediated angiogenesis pathway to upregulate VEGF in GC[70].

Tryptase

Preclinical trial: Tumor-infiltrating mast cells (TMs) secrete tryptase by binding to proteinase-activated receptor-2 (PAR-2) and then produce VEGF to stimulate tumor angiogenesis and EC proliferation, as demonstrated through in vitro and in vivo
assays. Clinical application: TIMs can release tryptase via PAR-2 activation and are involved in tumor angiogenesis. Ammendola et al. suggested that an increased mast cell density positive for tryptase (MCDPT) and a higher general vascularized area are related to poor survival outcome and can thus serve as potential targets in both primary tumor and lymph node metastases in GC patients.

RESULTS FROM PRECLINICAL AND CLINICAL STUDIES OF ANTIANGIOGENIC THERAPIES FOR GC

According to the results of studies on the molecular mechanism of tumor angiogenesis, we can develop a novel antiangiogenic strategy that could reduce tumor angiogenesis and limit tumor growth instead of eradicate the tumors and thereby delay the progression of precancer/primary lesion to metastases/aggressive cancers. The purpose of antiangiogenesis therapy is not to directly target cytotoxic tumor cells but rather block the supply of oxygen, growth factors and nutrition from blood vessels. Thus, this section will focus on several tumor angiogenic factors that could serve as potential targets for antiangiogenic drugs that are currently being investigated in preclinical (the section only highlights the most common antiangiogenic drugs; Table 1) and clinical studies on GC patients. Due to the metabolic changes and stemness of malignant cells lacking oxygen supply in various tumors, tumors appear to escape antiangiogenic therapy within a short time owing to the manipulation of alternative pathways, vasculogenic imitation and recruitment of bone marrow-derived cells. Various clinical trials have not shown a statistically significant extension of survival outcomes. Thus, most of the antiangiogenesis strategy can be ineffective. In phase III clinical trials, only ramucirumab (anti-VEGFR) and apatinib (VEGFR-TKI) have reported to improve ORR and prolong OS and PFS outcomes when used as a 2nd-line regimen combined with chemotherapy treatment in advanced GC (Table 2).

INHIBITORS OF PROANGIOGENIC LIGANDS AND RECEPTORS

Bevacizumab (avastin, genentech, rhumad)

Preclinical trial: As demonstrated in a preclinical model, this drug, which is a recombinant monoclonal antibody against VEGF-A, serves as a powerful and effective antiangiogenesis agent in several cancers. An in vitro study revealed that treatment with bevacizumab reduced cell growth and pro-apoptosis in GC cell lines. Yamashita-Kashima et al. performed an in vivo study and found that bevacizumab could be effective against GC and select biomarkers in the MKN-45 human gastric xenograft model. A study with mouse models revealed that treatment with bevacizumab significantly reduced the tumor size. In the future, we will explore the effects of the antibody-mediated blockage of VEGF-mediated tumor angiogenesis in GC to obtain a more in-depth understanding.

Clinical trial: Ohtsu et al. explored the effect of bevacizumab, which is a VEGF blocker. The AVAGAST clinical trial indicated that the 1st line treatment of advanced GC patients (multiethnic population) with bevacizumab in combination with chemotherapy (Cisplatin; Cis/Capcitabine; Cap) resulted in significantly improved ORR ($P = 0.0315$) and extended PFS ($P = 0.0037$) outcomes compared with those achieved with chemotherapy alone (Table 2). However, the AVATAR clinical trial showed that the 1st line treatment of advanced GC patients (China) with bevacizumab in combination with chemotherapy (Cis/Cap) did not significantly prolong the survival outcomes compared with those achieved with chemotherapy alone. In contrast, Ma et al. assessed the effects of bevacizumab in combination with chemotherapy (Docetaxel; Doc/OxaliPlatin; Oxa/5-FU) compared with those of the 1st line treatment of chemotherapy alone in advanced GC patients (China) and observed significantly improved ORR ($P = 0.0436$) and extended PFS ($P = 0.013$) outcomes compared with those achieved with chemotherapy alone. The other group, the ST03 clinical trial, showed that the perioperative treatment of advanced GC patients (United Kingdom) with bevacizumab in combination with chemotherapy (Cis/Cap/Epirubicin; Epi) had no positive results compared with those achieved with chemotherapy alone. However, the differences in the outcomes achieved after bevacizumab treatment among the different populations remain unknown.
| Target Category | Blockers | Country | Cancer type | Setting | Treatment | N | ORR (%) | DCR (%) | PFS (mo) | OS (mo) | Top 5 adverse events | Ref. |
|-----------------|----------|---------|-------------|---------|-----------|---|---------|---------|---------|---------|---------------------|------|
| Anti-VEGF       | Bevacizumab (Monoclonal Ab) | Multiethnic Asia-Pacific | Metastatic GC | 1st-line | Bevacizumab + Cis/Cap | 387 | 46% | 76.90% | 6.7 | 12.1 | Neutropenia, Fever, Neutropenia | AVA-GAST[114] |
|                 |          | Europe  | Recurrent GC | Placebo | 387 | 37.40% | 67.70% | 5.3 | 10.1 | Anemia | Decreased appetite | [115] |
|                 |          | Pan-America | Gastro-esophageal junction GC | + Cis/Cap | 102 | 33.70% | 72.10% | 6 | 11.4 | Diarrhea, Nausea | AVA-TAR[119] |
|                 |          | China   | Metastatic GC | Placebo | 100 | 40.70% | 75.30% | 6.3 | 10.5 | Neutropenia | Nausea, Intestinal obstruction | [116] |
|                 |          | China   | Unresectable locally advanced GC | + Cis/Cap | 40 | 65% | 30% | 15.2 | 17.6 | Vomiting, Sensory neuropathy | [117] |
| Anti-VEGFR      | Ramucirumab (Monoclonal Ab) | United Kingdom | Resectable GC | Peri-operative | Placebo | 530 | ND | ND | 48.10% | Lethargy, Nausea | (United Kingdoms Medical Research Council ST03)[118] |
|                 |          | United Kingdom | Esophageal gastric junction GC | Bevacizumab + Cis/Cap/Epi | Placebo | 533 | ND | ND | ND | Neutropenia, Diarrhea, Alopecia | [119] |
|                 |          | United Kingdom | Lower esophageal GC | | | | | | | Decreased appetite | [116] |

Source: WJGO https://www.wjgnet.com September 15, 2019 Volume 11 Issue 9

Hsieh HL et al. Angiogenesis in GC progression
### Table 1: Symptoms and Treatment Efficacy Across Different Subgroups

| Location                  | Treatment          | Placebo | + Pla/5-Fu | ND           | P       | P < 0.001 | P < 0.047 |
|---------------------------|--------------------|---------|------------|--------------|---------|-----------|-----------|
| South and Central America, India, South Africa, Middle East | Placebo            | 117     | 3%         | 23%          | 1.3     | 3.8       | Constipation |
| Multiethnic               | Advanced gastric GC | Ramucirumab | 330       | 28%          | 80%     | 4.4       | Fatigue |
| North and South America   | 2nd-line           | + Pac   |            | P = 0.76     | P < 0.001| P < 0.047 |
| Europe                    | Australia, Asia    | Placebo | 335        | 16%          | 64%     | 2.86      | 7.4       |
|                           | + Pac              |         |            | P < 0.001    | P = 0.0001| P < 0.0169 |
| Multiethnic               | Metastatic GC      | Ramucirumab | 326       | 41.10%       | 81.90%  | 10.2      | Neutropenia |
| North America             | 1st-line           | + Cis/5-Fu |            | P = 0.017    | P = 0.095| P = 0.68  |
| Europe                    | Japan              | Placebo  | 319        | 36.40%       | 76.50%  | 9.2       | 10.7      |
|                           | + Cis/5-Fu         |          |            | P < 0.001    | P < 0.001| P < 0.001 |          |
| VEGF TKI                  | apatinib China     | Metastatic GC | 176       | 2.84         | 42.05   | 2.6       | 6.5       |
|                           | Advanced GC        | Apatinib |            | P = 0.17     | P = 0.095| P = 0.64  |
|                           | Gastroesophageal junction GC | Placebo  | 91         | 0            | 8.79    | 1.8       | 4.7       |
|                           | + Cis/5-Fu         |          |            | P < 0.001    | P = 0.1695| P < 0.001 | P < 0.0149 |

A *P* value less than 0.05 indicates statistical significance according to the Mann-Whitney *U* test. VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; TKI: Tyrosine kinase inhibitor; ORR: Median overall response rate; DCR: Median disease control rate; PFS: Median progression-free survival; OS: Median overall survival; Cis: Cisplatin; Cap: Capecitabine; Doc: Docetaxel; Oxa: Oxaliplatin; 5-FU: 5-Fluorouracil; Epi: Epirubicine; Pla: Polylactic acid; Pac: Paclitaxel; HR: Hazard ratio; CI: Confidence interval.

### Interferon, rapamycin, and neovastat

**Preclinical trial:** The interferon family contains multifunctional cytokines that exhibit antiviral and antitumor properties, induce regulatory cell apoptosis and immune responses and inhibit proangiogenic factors. Abdel-Rahman *et al.*[90] evaluated bevacizumab in combination with other anticancer agents, such as mTOR inhibitors and interferon (IFN), as a more effective treatment for gastrointestinal tract and pancreatic tissues. Preclinical and clinical trials showed that other mTOR inhibitors, such as rapamycin, also display antiangiogenic activity in GC.[91] Moreover, Neovastat is a multifunctional drug that blocks VEGF, MMPs and proapoptotic activity in ECs. One MMP inhibitor (Marimastat) has been shown to induce positive outcomes in...
phase III clinical trials with advanced GC patients. The other MMP inhibitors are continuing to be investigated in clinical trials[22].

**Clinical trial:** A clinical phase II trial showed that the treatment of advanced GC patients with interferon-alpha 2B (IFN) and folinic acid (FA) in combination with 5-fluorouracil (5-FU) chemotherapy also resulted in significantly prolonged PFS outcomes compared with those achieved with chemotherapy alone[119]. Al-Batran et al[20] demonstrated that mTOR-mediated inhibitors (e.g., rapamycin) blocked the growth of GC cells and delayed tumor progression in cell lines and mouse models. Additionally, the mTOR inhibitor rapamycin has also yielded better survival outcomes in phase I/II studies of metastatic GC patients than do treatment without rapamycin.

**Ramucirumab**

**Preclinical trial:** Ramucirumab is a VEGFR-2-targeted monoclonal antibody that inhibits VEGFR-2 signaling. An *in vitro* study showed that treatment with ramucirumab also inhibited cell growth and promoted apoptosis in GC cell lines and animal models[95,96]. Thus, both bevacizumab and ramucirumab inhibit VEGF-mediated pathways in GC. Additionally, an *in vivo* study showed that the effects of combination therapy involving anti-VEGFR and anti-EGFR agents resulted in a significantly decreased tumor size in a GC mouse model[97].

**Clinical trial:** Fuchs et al[118] attempted to explore the effect of ramucirumab, which blocks VEGFR signaling. The REGARD clinical trial indicated that the treatment of advanced GC patients (multiethnic) with ramucirumab in combination with chemotherapy (Pla/5-Fu) resulted in significantly extended PFS (P = 0.0001) and OS (P = 0.047) outcomes compared with those achieved with placebo. Moreover, the RAINBOW clinical trial showed that the treatment of advanced GC patients (multiethnic) with ramucirumab in combination with chemotherapy (PacliTaxel; Pac) also resulted in significantly improved ORR (P < 0.0001) and DCR (P < 0.0001), extended PFS (P < 0.0001) and OS (P = 0.0169) outcomes compared with those achieved with chemotherapy alone[119]. In contrast, the RAUNFALL clinical trial showed that the treatment of advanced GC patients (multiethnic) with bevacizumab in combination with chemotherapy (Cis/5-Fu) had no positive results compared with those achieved with chemotherapy alone[20]. Ramucirumab was approved by the United States Food and Drug Administration (FDA) in 2014 as a 2nd-line treatment of advanced GC due to the REGARD and RAINBOW clinical trials and has beneficial effects on PFS and OS for advanced GC.

**DIRECT ACTION ON ECs**

**Regorafenib, apatinib, and foretinib**

**Preclinical trial:** Regorafenib, apatinib and foretinib belong to the family of multitargeting TKIs. Blockage of the effects of VEGF by silencing RNA in GC cell lines led to reduced tumor volume after implantation of these GC cells into nude mice[98]. The same effect was observed in mice treated with apatinib after tumor grafting[99].

**Clinical trial:** First, Li et al[121] explored the effect of apatinib, which VEGFR TKI blockade. A 116 clinical trial (3rd line) indicated that the treatment of advanced GC patients (China) with apatinib resulted in significantly improved ORR (P < 0.001), extended PFS (P < 0.001) and OS (P = 0.0149) outcomes compared with those achieved with placebo. In a phase II study, the tumor-angiogenesis inhibitor regorafenib, which targets VEGFR, TIE and multiple kinases, was evaluated in advanced GC patients, and the results showed that treatment with this inhibitor resulted in significantly prolonged PFS outcomes compared with those achieved with placebo[124]. Thus, regorafenib will be investigated in a phase III study. However, another antiangiogenic drug, foretinib, which inhibits VEGFR2 and TIE-2, did not yield any benefits in the survival outcomes of GC patients[120]. In addition, Shan et al[20] reviewed information from clinical trials evaluating antiangiogenic agents (with a focus on multitargeting TKIs) in advanced GC and found that only apatinib yielded a positive effect on PFS.

**Orantinib (SU5416, SU6668), Pazopanib, Sorafenib (Nexavar), Sunitinib (Sutent), Telatinib (Erbitux, Cetuximab)**

**Preclinical trial:** Orantinib (SU5416 SU6668)[94], pazopanib[100,101], sorafenib (Nexavar)[98,99,102,103] and telatinib (Erbitux, Cetuximab)[103] block tyrosine kinases and belong to the family of multitargeting TKIs. Suppressing the effects of VEGF by silencing RNA in GC cell lines led to decreased tumor...
angiogenesis and growth after these cells were implanted into nude mice.

**Clinical trial:** Chen et al. summarized the results from clinical trial phase II studies of antiangiogenic drugs, including VEGF ligands, VEGFRs and multitarget TKIs, in advanced GC. The treatment of advanced GC patients with orantinib, pazopanib, sorafenib, sunitinib, telatinib, and vandetanib resulted in significantly extended OS and PSF.

**Aflibercept**

**Preclinical trial:** Aflibercept traps VEGF and PlGF in vivo and is currently being investigated in a clinical trial (NCT01747551) as a supplement to standard chemotherapy for GC patients. In addition to VEGF-specific inhibition, the effect of HIF-1 blockage has been investigated in animal models in several studies. The treatment of subcutaneous xenografts with an inhibitory HIF-1 compound results in smaller and less vascularized tumors after implantation into nude mice.

**Trastuzumab**

Seidman et al. reported that the antibody trastuzumab blocks the Her2/neu receptor through the RAS-MAPK proliferation signaling pathway. A log-rank test showed improved survival outcomes in breast cancer patients. The comparison of two different Her2 and VEGF inhibitors revealed that the effect of tumor growth inhibition on Her2-overexpressing GC xenografts through the combination of Her2 and VEGF inhibitors was better than that achieved with either inhibitor alone.

**Nonsteroid anti-inflammatory drugs**

In an animal model, nonsteroid anti-inflammatory drug (NSAID)-mediated cyclooxygenase (COX) inhibition resulted in reduced tumor angiogenesis, and decreased HIF-1 expression was detected in GC cells after treatment with NSAIDs.

### OTHER ASSOCIATED CHEMOTHERAPIES

In clinical phase trials, cancer patients are typically administered combination therapy consisting of antiangiogenic agents with chemotherapeutic agents. However, antiangiogenic therapy sometimes elicits several adverse effects, such as hypertension or proteinuria, but the factors responsible for these adverse effects remain unknown. In general, the results from several studies on some antiangiogenic therapies, such as the inhibition of VEGF, Ang-1 and PlGF, indicate that antiangiogenic therapy not only inhibits EC migration and proliferation but also enhances chemotherapy ability. Hwang et al. indicated that the inhibition of VEGFR enhances paclitaxel sensitivity in GC cells. Another group of researchers showed that the upregulation of HIF-1 promotes chemotherapy and the antiapoptosis ability in GC cells by inducing miR-27a- or p53- and NF-kB-mediated pathways. Additionally, compared with normal blood vessels, tumor vessels exhibit heterogeneity, versatility, high permeability and vascular properties that benefit chemotherapy. Thus, antiangiogenic therapy could exert an adjuvant effect in chemotherapy.

### CONCLUSION

Tumor angiogenesis involves a complex multistep process. In general, the available knowledge indicates that proangiogenic and pro-oncogenic (such as proliferation, anti-apoptosis, migration and invasion) pathways are linked to each other. Thus, tumor angiogenesis occurs at different stages of tumor progression, including tumor growth, metastasis and recurrence. This connection can be clearly observed by the administration of combination therapy against angiogenic and proliferative pathways, such as the VEGF-, EGFR- and STAT3-mediated pathways. These transcription factors regulate cell growth, migration and angiogenesis in multiple ways.

First, we investigated the expression of angiogenic factors in GC through preclinical trials [cell line (in vitro)/animal model (in vivo)] and thus determined whether these factors could serve as predictive factors/biomarkers for proliferation, invasion or metastasis and/or have diagnostic or prognostic value. An increasing number of studies has revealed that antiangiogenic agents attack tumor ECs as their target instead of tumor cells themselves, which is the final goal of tumor dormancy therapy. Moreover, the therapeutic target of antiangiogenic agents is tumor ECs, which are more genetically stable, show increased homogeneity and have a lower alteration level; antiangiogenic drugs can interact with ECs directly, resulting in...
higher potency, decreased drug resistance and fewer side effects. We explored the combination of antiangiogenic drugs and cytotoxic anticancer (chemical) drugs to develop a highly effective strategy for the management of advanced GC. Thus, antiangiogenic drugs might be valuable for the long-term management of tumor dormancy because they do not induce the development of antiangiogenic drug resistance, and these drugs present fewer side effects. A few recent clinical trials have revealed that antiangiogenic therapy could potentially extend the survival outcomes of advanced GC patients.

DISCUSSION

In assessing the effectiveness of antiangiogenesis therapy, a clinical phase III trial showed that only ramucirumab (an anti-VEGFR antibody) and apatinib (VEGFR TKI blocker) achieved positive results (Table 2). Although both ramucirumab and bevacizumab are anti-VEGF drugs, bevacizumab (AVAGAST, AVATAR, ST03, Ma et al.) had no positive results on OS, while ramucirumab (REGARD, RAINBOW) was more effective targeted drug and exerted more positive results for OS in advanced GC. We suggested that this is because bevacizumab only binds to VEGF-A, whereas ramucirumab binds to VEGFR-2, which blocks more VEGFs. Therefore, ramucirumab could exert more effective antiangiogenic function due to the inhibition of more VEGF molecules. One possible reason is the differences in the targets of the angiogenic action. However, the differences in the ability of these two anti-VEGF drugs remain partially unknown. Furthermore, the different populations of GC patients might be another factor that affects the benefits of these drugs. In the AVAGAST and RAINBOW studies, the non-Asian subgroup (66.5%; RAINBOW) achieved a greater benefit in OS from antiangiogenic therapy than did the Asian subgroup (51%; AVAGAST). However, the effect of ramucirumab still lacks 1st-line chemotherapy evidence. The extent of the usefulness of ramucirumab still requires exploration in further trials in different ethnicities and upon delivery as a 1st-, 2nd- or 3rd-line chemotherapy. Additionally, in evaluating the safety of antiangiogenesis therapy, most adverse events related to antiangiogenesis are tolerable and controllable, including hypertension, neutropenia and wound healing (Table 2). Conversely, the Cougar-02 trial, a Doc+best supportive care (BSC) study, has a similar result for OS as the REGARD trial and was more cost effective. Finally, of the VEGFR TKIs, only apatinib in the phase III clinical trial showed extended PFS and OS in advanced GC patients. We recommend that chemotherapy in combination with ramucirumab (anti-VEGFR) and apatinib (VEGFR TKI) significantly improves the outcome in ORR, extended PFS, and OS in the management of advanced GC.

Here, this review only included phase III clinical trials published in English. Previous studies have found that the combination of antiangiogenic agents with chemotherapy may be beneficial for advanced GC in OS, but potential publication bias should be considered when construing these results. To reduce possible publication bias, we tried to search in multiple databases. Nevertheless, some restrictions were present in this systemic review and statistical analysis (e.g., meta-analysis) such as the small size of included studies, multiple drugs implemented and the high heterogeneity between different studies. Therefore, a larger cohort size, more standardized research and high statistical quality should be implemented in future studies to identify patients who would most likely benefit from antiangiogenic treatment. Thus, this review will provide basic (tumor angiogenesis) and clinical (antiangiogenic drugs) research for the survey of the management of GC treatments.

FURTHER CHALLENGES OF ANTIANGIOGENIC THERAPY

Although several phase III clinical trials have reported positive results, new vessels in tumors have pleomorphic features, including heterogeneity, flexibility, penetrability, various vascular biomarkers, and turbulent blood flow with no lymphatic vessels, and these unusual features make the delivery of therapeutic drugs difficult. Hence, there remain several obstacles regarding the translation of antiangiogenic strategies from animal models to clinical trials. The current problems regarding preclinical to clinical trials and the future directions for antiangiogenic therapy are discussed below.

In preclinical trials, we usually perform experiments in animals with xenografts of various tumor cells, but these models cannot represent spontaneous and orthotopic human cancers, particularly highly metastatic tumors. Therefore, antiangiogenic drugs are not effective for every organ in the body. Antiangiogenic drugs often yield
different results or side effects in preclinical and clinical trials.

In advanced GC, the tumor develops several ways of escaping treatment and rapidly activating angiogenic pathways. Ebos et al.\(^{[156]}\) reported that enhanced metastasis was treated with sunitinib in a mouse model. Another group found a similar result\(^{[159]}\). This may partly fail to translate to a survival benefit of antiangiogenic drugs in localized or nonmetastatic GC. Therefore, it is crucial to develop novel biomarkers that are able to predict the prognosis of antiangiogenic treatments for advanced GC. In clinical trials, to assess antiangiogenic therapies, newer imaging systems and/or substitute biomarkers should be established for monitoring tumor vessel functions. Antiangiogenic drugs induce tumor dormancy, which is different from the results of chemotherapy\(^{[180]}\).

The aims of managing GC are to reduce drug toxicity and adverse events and prolong survival. Therefore, the optimal biological dose and therapeutic schedule of antiangiogenic drugs should be established. Moreover, antiangiogenic drugs can be combined with chemotherapy and/or radiotherapy\(^{[194]}\).

According to previous studies, the clinical effect is quite different in individuals due to heterogeneity of the tumor. It is unclear which patients benefit most from angiogenesis inhibitors. The race/ethnicity of patients seems to influence the efficacy of antiangiogenic treatments on OS. The patients should be selected, and angiogenic factors should be detected before the administration of antiangiogenic drugs. Individual angiogenic profiling according to an individual’s genetic background remain a problem that need to be addressed.

**REFERENCES**

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol* 2006; 12: 354-362 [PMID: 16489633 DOI: 10.3748/wjg.v12.i3.354]
2. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006; 7: 309-315 [PMID: 16574546 DOI: 10.1016/S1470-2045(06)70623-4]
3. Wu CW, Lo SS, Shen KJ, Hsieh MC, Lui WY, Peng FK. Surgical mortality, survival, and quality of life after resection for gastric cancer in the elderly. *World J Surg* 2000; 24: 465-472 [PMID: 10706921 DOI: 10.1007/s002689910074]
4. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Bremminkjeijen SJ, Lips DJ, Vd Wurff AA, Boscka K, Coobergh JW. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. *Eur J Cancer* 2010; 46: 1101-1110 [PMID: 20219351 DOI: 10.1016/j.ejca.2010.02.013]

5. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration). Group Oba K, Paoletti X, Bang YJ, Blanke C, Bleiberg H, Burelowski T, Fuchs H, Michels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasaki M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. *Eur J Cancer* 2013; 49: 1565-1577 [PMID: 23352439 DOI: 10.1016/j.ejca.2012.12.016]
6. Esteller M. Epigenetics in cancer. *N Engl J Med* 2008; 358: 1148-1159 [PMID: 18337604 DOI: 10.1056/NEJMra072067]
7. Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. *Cancer Chemother Pharmacol* 2009; 63: 571-582 [PMID: 19083000 DOI: 10.1007/s00280-008-0881-9]
8. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. *Nature* 2001; 411: 375-379 [PMID: 11557145 DOI: 10.1038/35077241]
9. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. *Cancer Metastasis Rev* 2010; 29: 285-293 [PMID: 20393783 DOI: 10.1007/s10555-010-9224-5]
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]
11. Folkman J, Klugerblum M. Angiogenic factors. *Science* 1987; 235: 442-447 [PMID: 2432664 DOI: 10.1126/science.2432664]
12. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. *Semin Diagn Pathol* 1993; 10: 302-313 [PMID: 7511250]
13. Alsabti EA, Neubauer A, Uppal R, Tannenbaum SR, Esteller M. Epigenetics in cancer. *Nat Rev Cancer* 2008; 8: 593-595 [PMID: 18337604 DOI: 10.1038/nr1093]
14. Folkman J. Angiogenesis in cancer. *Science* 1989; 246: 442-447 [PMID: 2432664 DOI: 10.1126/science.2432664]
15. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. *Semin Diagn Pathol* 1993; 10: 302-313 [PMID: 7511250]
16. Alsabti EA. Tumor dormancy: a review. *J Cancer Res Clin Oncol* 1979; 95: 209-220 [PMID: 393706 DOI: 10.1007/BF00410641]
17. Bergh J, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003; 3: 401-410 [PMID: 12787810 DOI: 10.1038/nrc1093]
18. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1989; 328: 1182-1186 [PMID: 24938153 DOI: 10.1056/NEJM197911182852108]
19. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. *Nature* 2003; 423: 593-595 [PMID: 12789320 DOI: 10.1038/43293a]
20. Haisman AL. Hypoxia--a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002; 2: 38-47 [PMID: 11902584 DOI: 10.1038/nc1074]
21. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends Mol Med* 2002; 8: 562-567 [PMID: 11927290 DOI: 10.1016/S1471-4914(02)03171-7]
22. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. *Cancer Res* 1999; 59: 5830-5835 [PMID: 10582706]
23. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? *J Clin Invest* 2007; 117: 862-865 [PMID: 1740612 DOI: 10.1172/JCI31750]
24. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003; 3: 721-732 [PMID: 1310303]
Angiogenesis in GC progression

Yeong EU, Chen YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: a potential anticancer drug targeting hypoxia-inducible factor-1. J Natl Cancer Inst 2003; 95: 516-523 [PMID: 12670109 DOI: 10.1093/jnci/djg57]

Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, Ellis LM. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946-956 [PMID: 15199114 DOI: 10.1093/jnci/djh168]

Olst B, Wagner S, Sewing KF, Beil W. Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 2009; 31: 1111-1115 [PMID: 19083697 DOI: 10.1093/carcin/bgn115]

Park JH, Kim TY, Joung HS, Kim TY, Chun YS, Park JW, Lee CT, Jung HC, Kim NK, Bang YJ. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res 2003; 9: 433-440 [PMID: 12538497]

Bone S, Deininger M, Gora-Tybor J, Goldmann JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367 [PMID: 9787174]

Adam RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-478 [PMID: 17522591 DOI: 10.1038/nrm2183]

Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660 [PMID: 12778167 DOI: 10.1038/nm0603-653]

Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70 [PMID: 7596436 DOI: 10.1038/3760646a]

Fong GH, Zhang L, Breyer DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999; 126: 3015-3025 [PMID: 10357944]

Karar J, Maity A. PI3K/ATK/mTOR Pathway in Angiogenesis. Front Mol Neurosci 2011; 4: 51 [PMID: 22449466 DOI: 10.3389/fnmol.2011.00051]

Bruck RK, McKnight SL. A conserved family of poly(ADP-ribosyl)transferases that modify HIF. Science 2001; 294: 1337-1340 [PMID: 11598268 DOI: 10.1126/science.1063737]

Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009; 89: 607-648 [PMID: 19342615 DOI: 10.1523/jpysc.00031.2008]

Shalaly F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schul AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66 [PMID: 7596435 DOI: 10.1038/3760626a]

Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhaute A, Harpal K, Eberhardt C, Declere C, Pawling J, Moostaei M, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439 [PMID: 8602241 DOI: 10.1038/380435a0]

Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442 [PMID: 8602246 DOI: 10.1038/380439a0]

Shi J, Wei PK. Interleukin-8: A potent promoter of angiogenesis in gastric cancer. Oncol Lett 2016; 11: 1043-1050 [PMID: 26893688 DOI: 10.3892/ol.2015.4035]

Xu WH, Ge YL, Li Q, Zhang X, Duan JH. Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells. World J Gastroenterol 2009; 15: 2044-2047 [PMID: 19815403 DOI: 10.3748/wjg.v13.i14.2044]

Forsythe JA, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Mol Cell Biol 2001; 21: 4604-4613 [PMID: 1128/MCB.16.9.4604]

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 [PMID: 12778165 DOI: 10.1038/nrn0603-669]

Karayannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kourakis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42 [PMID: 12131083 DOI: 10.1097/00000658-200207000-00007]

Kakeji Y, Koga T, Sumiyoshi Y, Shibahara K, Oda S, Maehara Y, Sugiuchi K. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002; 21: 125-129 [PMID: 12071518 DOI: 10.31021/jecr20181111]

Wong TB, Wang J, Wei XQ, Wei B, Dong WG. Serum vascular endothelial growth factor-C combined with multi-detector CT in the preoperative diagnosis of lymph node metastasis of gastric cancer. Asia Pac J Clin Oncol 2012; 8: 180-186 [PMID: 22524577 DOI: 10.1111/jpc.12014.9000]

Kikuchi S, Obata Y, Yagyu K, Lin Y, Nakajima T, Kobayashi O, Kikuchi M, Ushijima R, Kurosawa M, Ueda J. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients. Cancer Sci 2011; 102: 866-869 [PMID: 21219538 DOI: 10.1111/j.1349-7006.2011.01860.x]

Sheng SL, Bao SH, Huang G, Wang LM. Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric cancer. Clin Exp Immunol 2008; 151: 459-466 [PMID: 18234057 DOI: 10.1111/j.1365-2249.2007.03548.x]

Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, Castells A, Pera M. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009; 96: 1443-1451 [PMID: 19918848 DOI: 10.1002/bjs.6780]

Villarejo-Campos P, Padilla-Valverde D, Martin RM, Menéndez-Sánchez P, Cubo-Cintas T, Bondía-Navarro JA, Fernández JM. Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol 2013; 15: 265-270 [PMID: 22855190 DOI: 10.1007/s12094-012-0998-x]

Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371 [PMID: 16633338 DOI: 10.1038/nrm1911]

Akrami H, Mahmoudi F, Havasi S, Sharifi A. PI3K inhibition inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways. Cell Biochem Funct 2016; 34: 173-180 [PMID: 26968576 DOI: 10.1002/cbf3176]
Hsieh HL et al. Angiogenesis in GC progression

Mahmoodi F, Akrami H. PIGF Knockdown Decreases Tumorigenicity and Stemness Properties of Spheroid Body Cells Derived from Gastric Cancer Cells. J Cell Biochem 2017; 118: 851-859 [PMID: 27235991 DOI: 10.1002/jcb.23762]

Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004; 213: 73-82 [PMID: 15312686 DOI: 10.1016/j.canlet.2004.05.020]

Li Li, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33: 531-541 [PMID: 22848522 DOI: 10.1016/j.tips.2012.07.001]

Forough R, Weybie B, Patel C, Ambrosia S, Singh US, Zhu J. Role of Akt/PKB signaling in fibroblast growth factor-1 (FGF-1)-induced angiogenesis in the chicken chorioallantoic membrane (CAM). J Cell Biochem 2005; 94: 109-116 [PMID: 15517595 DOI: 10.1002/jcb.20274]

Sahin F, Celik HA, Aydin HH, Oktem G, Ormay SB, Saydam G. The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. Hematol J 2008; 9: 215-228 [PMID: 18796247 DOI: 10.1111/j.1528-0006.2007.01597]

Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008; 41: 278-286 [PMID: 18452647 DOI: 10.5483/BMBRep.2008.41.4.278]

Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 1994; 125: 917-928 [PMID: 7514607 DOI: 10.1083/jcb.125.4.917]

Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galt D, Cao R, Hosaka K, Cao Y. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2011; 18: 100-110 [PMID: 21238574 DOI: 10.1038/nm.2375]

Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcuoss FG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gpl30 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738 [PMID: 18431520 DOI: 10.1172/JCI32449]

Singh R, Kim WJ, Kim PH, Hong HS. Combined blockade of HER2 and VEGF/Flt-1 offers greater inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med 2013; 45: e52 [PMID: 24176949 DOI: 10.1038/emlm.2013.111]

Laughter E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004 [PMID: 11539097 DOI: 10.1128/MCB.21.12.3995-4004.2001]

Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6969-6976 [PMID: 17615132 DOI: 10.1038/sj.onc.120965]

Seidman AD, Formier MN, Esteva TJ, Tan L, Kaptain S, Bach A, Panages KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Mohyana ME, Moassser M, Sklarin N, Dickler M, Dandrea A, Cristofanilli M, Rivera E, Hertobagy GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595 [PMID: 11352850 DOI: 10.1200/JCO.2001.19.10.2587]

Angustine HG, Koh GY, Thurston G, Altitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-177 [PMID: 19234476 DOI: 10.1038/nrm2639]

Saharinen P, Byr M, Altitalo K. How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 2010; 17: 198-205 [PMID: 20737888 DOI: 10.1097/MOH.0b013e32833f577]

Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radojczewski C, Mainsioniere PC, Yanopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169 [PMID: 8902233 DOI: 10.1083/jcb.165.4.8902233]

Mainsioniere PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, McClain J, Davis S, Sato T, Yanopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60 [PMID: 9204896 DOI: 10.1126/science.277.5322.55]

Fagian J, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013; 328: 18-26 [PMID: 22922303 DOI: 10.1016/j.canlet.2012.08.018]

Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008; 10: 513-526 [PMID: 18425120 DOI: 10.1038/nclb.2008.92]

Saharinen P, Eklund L, Mittemen J, Wirkkala R, Anisimov A, Winderlich M, Vestweber D, Deutsch U, Koh GY, Olsen BR, Altitalo K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008; 10: 527-537 [PMID: 18421159 DOI: 10.1038/nclb.2008.92]

Wang J, Wu KC, Zhang DX, Fan DM. Antisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer. World J Gastroenterol 2006; 12: 2450-2454 [PMID: 16688431 DOI: 10.3748/wjg.v12.i15.2450]

Chen Z, Zhu S, Hong J, Souto M, Peng D, Belkhiri A, Xu Z, El-Rifai W. Gastric tumour-derived ANGPT2 regulation by DARRP-32 promotes angiogenesis. Gut 2016; 65: 925-934 [PMID: 25779598 DOI: 10.1136/gutjnl-2014-308410]

Ou XL, Chen HJ, Sun Will, Hang C, Yang L, Guan YY, Yan F, Chen BA. Effects of angiopoietin-1 on attachment and metastasis of human gastric cancer cell line BGC-823. World J Gastroenterol 2009; 15: 5432-5441 [PMID: 19916173 DOI: 10.3748/wjg.v15.i25.5432]

Tang S, Wang D, Zhang Q, Li L. miR-218 suppresses gastric cancer cell proliferation and invasion via regulation of angiopoietin-2. Exp Ther Med 2016; 12: 3837-3842 [PMID: 28105117 DOI: 10.3892/etm.2016.3801]

Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, Schmidt T, Ott K. Angiogenic and growth factors in gastric cancer. J Surg Res 2015; 194: 420-429 [PMID: 25577146 DOI: 10.1016/j.jss.2014.11.028]

Dreikhausen L, Blank S, Sisic L, Heger U, Weichert W, Jager D, Bruckner T, Giese N, Grenacher L, Falk C, Ott K, Schmidt T. Association of angiogenic factors with prognosis in esophageal cancer. BMC Cancer
The text on the page appears to be a continuation of a scientific article discussing the impact of various factors on gastric cancer progression and treatment. The content includes references to multiple studies and studies involving biomarkers and therapeutic strategies. It appears to be a page from a scientific journal, possibly discussing a specific aspect of gastric cancer, such as angiogenesis and its therapeutic implications. The text is technical and includes references to specific studies and surgical procedures, indicating a detailed and focused discussion on the subject matter.
Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer:
Bernhard H, Klein O, Wächter B, Theiss F, Dippold W, Meyer zum Büschenfelde KH, Knuth A.

Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Regard Trial Investigators.

Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178 [PMID: 15863032 DOI: 10.1016/j.cytogfr.2005.01.004]

Folberg R, Hendrix MJ, Maniotis AJ. Vascularogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-381 [PMID: 10663634 DOI: 10.1002/1096-0868(200002)156:2<361::AID-Amjpath1>3.0.CO;2-Q]

Lunghi E, Botticelli C, Carboni M, Cugno M, Foppagni V. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 2010; 296: 249-256 [PMID: 20471160 DOI: 10.1016/j.clet.2010.04.015]

Hsieh HL. Angiogenesis in GC progression. Cancer Lett 2010; 296: 249-256 [PMID: 20471160 DOI: 10.1016/j.clet.2010.04.015]
Hsieh HL et al. Angiogenesis in GC progression

10.1093/oxfordjournals.oncdev.a059110

Al-Batran SE, Ducrée M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012; 130: 491-496 [PMID: 21983386 DOI: 10.1002/ijc.26396]

Pavlakis S, Sjoquist KM, Martin AJ, Tsoobanis E, Yip S, Kang YK, Bang YJ, Alcinodor T, O’Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lippton LR, Wong M, Strickland A, Kim JW, Zalceberg JR, Simes J, Goldstein D. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol 2016; 34: 2728-2735 [PMID: 27235864 DOI: 10.1200/JCO.2015.65.1901]

Shafor MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Junz P, Lee FC, Kallender H, Cecchi C, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8: e54014 [PMID: 23516391 DOI: 10.1371/journal.pone.0054014]

Shan F, Miao R, Xue K, Li Z, Bu Z, Wu A, Zhang L, Wu X, Zong X, Wang X, Li S, Jia J, Zai L, Ji J. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. Cancer Lett 2016; 380: 598-607 [PMID: 26724881 DOI: 10.1016/j.canlet.2015.12.023]

Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Nat Rev Oncol 2005; 7: 452-464 [PMID: 16212810 DOI: 10.1038/nrn1678-022]

Izzedine H, Edery S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807-815 [PMID: 19150949 DOI: 10.1093/annonc/mdm173]

Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20: 13343-13368 [PMID: 25390990 DOI: 10.3748/wjg.v20.i48.13343]

Gim S, Alexander IE, Edelstein ML, Abdi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77 [PMID: 23355455 DOI: 10.1002/jgm.2698]

ortíz R, Melguizo C, Prados J, Álvarez PJ, Caba O, Rodríguez-Serrano F, Hita F, Áraneaga A. New gene therapy strategies for cancer treatment: a review of recent patents. Recent PatAnticancer Drug Discov 2012; 7: 297-312 [PMID: 23393858 DOI: 10.2174/174992201280100286]

Cao S, Cripps A, Wei MQ. New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol 2010; 37: 108-114 [PMID: 19671071 DOI: 10.1111/j.1440-1618.2009.05268.x]

Tseng SJ, Liao ZX, Kao SH, Zeng YF, Huang KY, Li HJ, Yang CL, Deng YF, Huang CF, Yang SC, Yang PC, Kemptson IM. Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour. Nat Commun 2015; 6: 6456 [PMID: 25739372 DOI: 10.1038/ncomms7456]

Tazawa K, Kagawa S, Fujiwara T. Advances in adenosine-mediated p53 cancer gene therapy. Expert Opin Biol Ther 2013; 13: 1569-1583 [PMID: 24017188 DOI: 10.1517/14712598.2013.845662]

Prabhha S, Sharma B, Labhasetwar V. Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice. Cancer Gene Ther 2012; 19: 530-537 [PMID: 22559792 DOI: 10.1038/cgt.2012.26]

Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl) 2007; 85: 1175-1186 [PMID: 17589815 DOI: 10.1007/s00109-007-0221-2]

Chang C, Wang QT, Liu H, Zhang ZZ, Huang WL. Advancement and prospects of tumor gene therapy. Chin J Cancer 2011; 30: 182-188 [PMID: 21352695 DOI: 10.5732/cjc.010.10074]

Allen JW, Moon J, Redman D, Gadee GM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahnzeb M, Gandara DR. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 2014; 32: 2463-2470 [PMID: 25002722 DOI: 10.1200/JCO.2013.51.4109]

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalceberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Winters I, Ringash J, Tu D, O’Callaghan CJ. Phase III randomized, placebo-controlled study of cetuximab plus paclitaxel and carboplatin for patients with advanced/metastatic non-small cell lung cancer. J Clin Oncol 2014; 32: 490-499 [PMID: 23594786 DOI: 10.1001/sjco.2014.3702-5]

Hiré E, Badai B, Takaci-Nagy Z, Rubovszky G, Tóth E, Renemár É, Polgár C, Láng I. Cетuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013; 109: 1117-1122 [PMID: 23942070 DOI: 10.1038/bjc.2013.468]

Österlund P, Soervert LM, Isoniemi H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011; 104: 599-604 [PMID: 21304526 DOI: 10.1038/bjc.2011.2]

Tahever E, Uziely B, Salah A, Tempier M, Peretz T, Hasán J. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol 2014; 48: 430-434 [PMID: 24153157 DOI: 10.1097/MCG.0b013e328a80048]

Hwang JE, Lee JH, Park MR, Kim DE, Bae WK, Shim HJ, Cho SH, Chung JJ. Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Oncol Rep 2013; 34: 374-380 [PMID: 23364970 DOI: 10.3842/ory.2013.52.374]

Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008; 99: 121-128 [PMID: 17953712 DOI: 10.1111/j.1349-7006.2007.00678.x]

Zhai Q, Li Y, Tan BH, Fan LQ, Yang PG, Tian Y. HIF-1 Targeted Multidrug Resistance in Gastric Cancer

WJGO | https://www.wjgnet.com

September 15, 2019 | Volume 11 | Issue 9

703
Cancer Cells by Inducing MiR-27a. PLoS One 2015; 10: e0132746 [PMID: 26292288 DOI: 10.1371/journal.pone.0132746]

Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T. Hypoxia-inducible factor alpha determines gastric cancer chemoresponsivity via modulation of p53 and NF-kappaB. PLoS One 2010; 5: e12038 [PMID: 20706634 DOI: 10.1371/journal.pone.0012038]

Groenewald P, Bradshaw D, Neethling I, Martin LJ, Dempers J, Morden E, Zinyakatira N, Coetzee D. Linking mortuary data improves vital statistics on cause of death of children under five years in the Western Cape Province of South Africa. Trop Med Int Health 2016; 21: 114-121 [PMID: 26483307 DOI: 10.1111/tmi.12624]

Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y. Angiogenesis as a target for gastric cancer. Surgery 2002; 131: S48-S54 [PMID: 11821787]

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyle D, Madhusudan S, Middleton GW, Swinson D, Fall S, Chau I, Cunningham D, Karczas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. DocaTaxel versus active symptom control for refractory oesophagealgastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86 [PMID: 24332238 DOI: 10.1016/S1470-2045(13)70549-7]

Lei X, Wang F, Ke Y, Wei D, Gu H, Zhang Z, Jiang L, Lv L, Liu J, Wang L. The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96: e6301 [PMID: 28272258 DOI: 10.1097/MD.0000000000006301]

Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther 2018; 11: 7077-7087 [PMID: 30410364 DOI: 10.2147/OTT.S169484]

Nelson NJ. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst 1998; 90: 960-963 [PMID: 9665141 DOI: 10.1093/jnci/90.13.960a]

Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol 2000; 29: 336-343 [PMID: 10817134 DOI: 10.1093/ije/29.2.336]

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239 [PMID: 19249681 DOI: 10.1016/j.ccr.2009.01.021]

Páez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231 [PMID: 19249680 DOI: 10.1016/j.ccr.2009.01.027]
